SAN DIEGO--(BUSINESS WIRE)--Artes Medical, Inc. (Nasdaq:ARTE), a medical technology company whose product ArteFill® is the first and only FDA-approved non-resorbable injectable dermal filler for the correction of nasolabial fold or “smile line” wrinkles, today announced that Douglas Abel, Chief Executive Officer and President of Manhattan Pharmaceuticals, Inc., has joined its Board of Directors. Mr. Abel previously served as Vice President of the Dermatology Business Unit of Biogen Idec, Inc. He also formerly served as Director of Marketing, Botox®, at Allergan, Inc. and prior to that, as a Senior Product Manager in Allergan’s skin care division.
